Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Videos

Rucaparib Promising for BRCA–Positive Relapsed Ovarian Cancer: Results From the ARIEL4 Trial


David O'Malley, MD, highlights promising results from a subgroup analysis of the effect of platinum sensitivity on the efficacy of rucaparib vs chemo for BRCA+, advanced, relapsed ovarian carcinoma.

Advertisement

Advertisement

Advertisement

Advertisement